INMUNE BIO INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
INMUNE BIO INC. (INMB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.18 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-27
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-12-31 was $72.00K.
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-09-30 was -$2.03M.
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-06-30 was $1.01M.
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-03-31 was $2.13M.
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $1.18M, a 38.01% decline from fiscal 2023.
- INMUNE BIO INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $1.91M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.96M derived: sum of 2 quarters · filed 2025-03-27 | -$952.00K derived: sum of 3 quarters · filed 2025-03-27 | $1.18M 10-K · filed 2025-03-27 |
| 2024-09-30 | -$2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$1.02M derived: sum of 2 quarters · filed 2024-10-31 | $1.11M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.14M 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | $2.13M 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $1.91M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |